Zepbound Surges, Orforglipron Impresses, and Lilly Keeps the Crown. For Now.
Eli Lilly released their Q1 2025 earnings this morning, and the story is clear. The GLP-1 race belongs to them. While they showed strength in all the usual areas, Mounjaro, Zepbound, and market share, the most important clues are buried in what comes next.
Here is the breakdown.
Keep reading with a 7-day free trial
Subscribe to On The Pen to keep reading this post and get 7 days of free access to the full post archives.